Basic information Safety Supplier Related

PF 05175157

Basic information Safety Supplier Related

PF 05175157 Basic information

Product Name:
PF 05175157
Synonyms:
  • 1-isopropyl-1'-(2-methyl-1H-benzo[d]imidazole-5-carbonyl)-4,6-dihydrospiro[indazole-5,4'-piperidin]-7(1H)-one
  • 1,4-Dihydro-1'-[2-methyl-1H-benzimidazol-6-yl)carbonyl]-1-(1-methylethyl)-spiro[5H-indazole-5,4'-piperidin]-7(6H)-one
  • CS-2573
  • PF 05175157;PF-05175157
  • PF 05175157
  • Spiro[5H-indazole-5,4'-piperidin]-7(6H)-one,1,4-dihydro-1'-[(2-methyl-1H-benzimidazol-6-yl)carbonyl]-1-(1-methylethyl)-
  • PF-05175157 >=98% (HPLC)
  • 1'-(2-methyl-1H-1,3-benzodiazole-6-carbonyl)-1-(pr opan-2-yl)-1,4,6,7-tetrahydrospiro[indazole-5,4'-pi peridin]-7-one
CAS:
1301214-47-0
MF:
C23H27N5O2
MW:
405.49
Product Categories:
  • API
Mol File:
1301214-47-0.mol
More
Less

PF 05175157 Chemical Properties

Boiling point:
692.0±55.0 °C(Predicted)
Density 
1.38±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMSO:20.0(Max Conc. mg/mL);49.38(Max Conc. mM)
form 
A crystalline solid
pka
11.47±0.10(Predicted)
color 
White to off-white
More
Less

PF 05175157 Usage And Synthesis

Uses

PF-05175157 has been used as an acetyl-Coenzyme A carboxylase (ACC) inhibitor to study its effects on the infection of flavivirus.

Biological Activity

PF-05175157 is a potent and selective inhibitor of both acetyl-CoA carboxylase isoform ACC1 located primarily in liver and adipose tissue and isoform ACC2 dominant in skeletal and heart muscle, with IC50 values of 27 nM and 33 nM, respectively. Acetyl CoA carboxylase (ACC) generates malonyl CoA, which is a substrate for de novo lipogenesis and is also an inhibitor of mitochondrial fatty acid β-oxidation through inihbition of carnitine-palmitoyl transferase I (CPT-1), responsible for the transport of long-chain fatty acyl-CoAs across the mitochondrial membrane. ACC inihibitors are hoped to inhibit de novo lipogenesis and increase β-oxidation of long-chain fatty acids with potential for treatment of type 2 diabetes, hepatic steatosis, and cancer. In Phase I clinical studies for diabetes treatment, PF-05175157 inhibited de novo lipogenesis and increased net whole-body fatty acid utilization.

storage

Store at +4°C

PF 05175157Supplier

Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
MedChemexpress LLC
Tel
021-58955995
Email
sales@medchemexpress.cn
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399 18927568969
Email
isunpharm@qq.com
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185 18149758185
Email
sales-cpd@caerulumpharma.com
Shanghai Xingui Biotechnology Co., Ltd.
Tel
17501653713
Email
xingui2022@126.com